OBJECTIVE： To observe the clinical efficacy and safety of citalopram in the treatment of functional gastrointestinal disorders complicated with anxiety or depression.  METHODS： 62 patients with functional gastrointestinal disorders complicated with anxiety or depression were randomly divided into treatment group （34 cases） and control group （28 cases）. Control group was given routine treatment， treatment group was additionally given Citalopram tablet with initial dose of 10 mg， qd， increasing to 40 mg qd， according to the situation of patients， on the basis of control group. Treatment course of 2 groups lasted for 3 months. The gastrointestinal symptom integral， HAMD and HAMA were compared between 2 groups before and after treatment， and clinical efficacy and the occurrence of ADR were observed. RESULTS： There was no statistical significance in gastrointestinal symptom integral， HAMD and HAMA between 2 groups before treatment （P＞0.05）. After Treatment， above scores of 2 groups decreased significantly， and the treatment group was lower than the control group， with statistical significance （P＜0.05）. Total effective rate of treatment group was significantly higher than that of control group （94.12％ vs. 67.86％）， with statistical significance （P＜0.05）. Olny 4 patients of treatment group suffered from mild ADR. CONCLUSIONS： Citalopram shows significant therapeutic efficacy in the treatment of  functional gastrointestinal disorders complicated with anxiety or depression， and can improve digestive tract symptom and anxiety or depression， and help to improve patients’ gastrointeseinal symptoms with good safety.